MITA Antibody STING1/8129R / Mediator of IRF3 Activation Antibody [clone STING1/8129R] (V5100)

MITA Antibody STING1/8129R in Human Tonsil IHC. Immunohistochemistry staining of FFPE human tonsil tissue with MITA Antibody, clone STING1/8129R. HIER was performed by boiling tissue sections in pH 9 10 mM Tris with 1 mM EDTA for 20 min followed by cooling before testing. Strong, widespread brown cytoplasmic staining is present throughout much of the lymphoid tissue, while the PBS negative control inset shows minimal background signal. The staining demonstrates detection of STING1, also known as Mediator of IRF3 Activation, in human tonsil.

MITA Antibody STING1/8129R in Human Spleen IHC. Immunohistochemistry staining of FFPE human spleen tissue with MITA Antibody, clone STING1/8129R. HIER was performed by boiling tissue sections in pH 9 10 mM Tris with 1 mM EDTA for 20 min followed by cooling before testing. Strong cytoplasmic immunoreactivity is evident in numerous cells surrounding a comparatively weakly stained lymphoid region, producing a clearly heterogeneous staining pattern. The result demonstrates detection of Mediator of IRF3 Activation/STING1 in human spleen tissue.

MITA Antibody STING1/8129R in Human Serous Ovarian Carcinoma IHC. Immunohistochemistry staining of FFPE human serous ovarian carcinoma with MITA Antibody, clone STING1/8129R. HIER was performed by boiling tissue sections in pH 9 10 mM Tris with 1 mM EDTA for 20 min followed by cooling before testing. Strong brown cytoplasmic staining is visible in numerous cells throughout the carcinoma, with particularly prominent immunoreactivity associated with epithelial tumor structures and surrounding cells. This result demonstrates detection of Mediator of IRF3 Activation/STING1 in human serous ovarian carcinoma.

MITA Antibody STING1/8129R in Human Prostate Carcinoma IHC. Immunohistochemistry staining of FFPE human prostate carcinoma tissue with MITA Antibody, clone STING1/8129R. HIER was performed by boiling tissue sections in pH 9 10 mM Tris with 1 mM EDTA for 20 min followed by cooling before testing. Cytoplasmic staining is evident throughout the specimen, with prominent brown immunoreactivity surrounding glandular structures and within intervening stromal areas. The heterogeneous staining demonstrates detection of STING1, also known as Mediator of IRF3 Activation, in human prostate carcinoma.

MITA Antibody STING1/8129R in Human Mammary Cancer IHC. Immunohistochemistry staining of FFPE human mammary cancer tissue with MITA Antibody, clone STING1/8129R. HIER was performed by boiling tissue sections in pH 9 10 mM Tris with 1 mM EDTA for 20 min followed by cooling before testing. The image shows heterogeneous brown immunoreactivity concentrated primarily within cellular regions bordering relatively unstained adipose spaces, with additional focal staining elsewhere in the specimen. This result demonstrates detection of Mediator of IRF3 Activation/STING1 in human mammary cancer tissue.

MITA Antibody STING1/8129R in Human Renal Cell Carcinoma IHC. Immunohistochemistry staining of FFPE human renal cell carcinoma with MITA Antibody, clone STING1/8129R. HIER was performed by boiling tissue sections in pH 9 10 mM Tris with 1 mM EDTA for 20 min followed by cooling before testing. Strong brown cytoplasmic staining is present in numerous carcinoma cells, with marked regional heterogeneity and areas showing comparatively little immunoreactivity. The staining demonstrates detection of STING1, also known as Mediator of IRF3 Activation, in human renal cell carcinoma.